TABLE 7.
FDA and EMA approved cytokines drugs for various cancer treatments.
| Cytokines | Trade name, manufacturer | FDA approval date | Type of cancer treated | References |
| Recombinant interleukin (IL)-2 | Aldesleukin, (Proleukin, Chiron) | 1992 | 1. Metastatic melanoma | (209, 210) |
| 2. Renal cell carcinoma (RCC) | ||||
| Recombinant alpha 2a | IFN-α2a (Roferon®-A, Roche) | 1986 | 1. Hairy cell lymphoma | (210–212) |
| 2. Chronic myelogenous leukemia (CML) | ||||
| 3. Melanoma (not successful due to toxicity) | ||||
| Recombinant alpha 2b | IFN-α2b (Intron® –A, Merck) | 1986 | 1. AIDS-related Kaposi’s sarcoma | (213–216) |
| 2. Melanoma | ||||
| 3. Follicular lymphoma | ||||
| 4. Multiple myeloma | ||||
| 5. Hairy cell leukemia | ||||
| 6. Cervical intraepithelial neoplasm |